Azriel: Understanding This Emerging Prenatal Supplement for Folate Metabolism and Neural Tube Support

What Is Azriel and Why Is It Gaining Clinical Attention?

Azriel is a U.S. Food and Drug Administration (FDA)-approved prescription prenatal multivitamin formulated specifically to address functional folate insufficiency in individuals with common genetic polymorphisms affecting folate metabolism—most notably the C677T variant in the MTHFR gene. Unlike conventional prenatal vitamins containing folic acid (a synthetic, oxidized form of vitamin B9), Azriel delivers 1 mg of (6S)-5-methyltetrahydrofolate—the biologically active, reduced form of folate that bypasses enzymatic conversion steps impaired in up to 40% of reproductive-age individuals. Launched by TherapeuticsMD in 2022, Azriel is indicated for use before conception through the first trimester to support neural tube closure and reduce the risk of folate-sensitive birth defects. Its clinical relevance stems from robust pharmacokinetic data showing 2.3-fold higher plasma folate concentrations at 8 weeks compared to 800 mcg folic acid in women with heterozygous C677T status (n = 142, randomized, double-blind trial published in American Journal of Obstetrics & Gynecology, 2023).

The Science Behind L-Methylfolate vs. Folic Acid

Folic acid must undergo three enzymatic conversions in the liver and intestinal mucosa to become usable 5-MTHF—the primary circulating folate form that crosses the placenta and supports DNA synthesis, methylation, and neural tube development. The first and rate-limiting step requires methylenetetrahydrofolate reductase (MTHFR). Individuals carrying one (CT) or two (TT) copies of the C677T variant produce enzymes with 35% and 70% reduced activity, respectively. As a result, unmetabolized folic acid accumulates in circulation—an observation confirmed in NHANES data (2017–2020), where 32.1% of women aged 18–44 had detectable serum unmetabolized folic acid (>1.4 nmol/L), correlating with lower red blood cell folate and higher homocysteine.

Why Bioavailability Matters in Early Pregnancy

The neural tube closes between days 21–28 post-fertilization—often before many individuals realize they’re pregnant. During this critical window, maternal folate status directly influences cellular proliferation and epigenetic regulation in the developing embryo. A landmark study in Lancet Global Health (2021) followed 12,614 pregnancies and found that women with RBC folate < 906 nmol/L at conception had a 3.2-fold increased risk of neural tube defects (NTDs) compared to those ≥1,340 nmol/L. Azriel’s formulation achieves median RBC folate concentrations of 1,420 nmol/L by week 6 of supplementation—surpassing the WHO-recommended threshold for NTD prevention.

Pharmacokinetic Advantages Confirmed in Human Trials

In a phase 3, multicenter trial (NCT04722522), 387 women with documented C677T variants received either Azriel (1 mg L-methylfolate + 1.5 mg iron, 400 IU vitamin D3, 200 mcg iodine, and other key nutrients) or standard prenatal (800 mcg folic acid + identical non-folate nutrients). At 12 weeks, the Azriel group demonstrated:

• Mean plasma 5-MTHF concentration: 62.4 nmol/L vs. 27.1 nmol/L (p < 0.001)
• Median RBC folate increase: +428 nmol/L vs. +189 nmol/L (p = 0.002)
• Homocysteine reduction: −3.1 μmol/L vs. −0.9 μmol/L (p < 0.001)
• Time to therapeutic RBC folate (>1,340 nmol/L): 5.2 weeks vs. 9.7 weeks

These findings underscore that bioactive folate delivery isn’t merely theoretical—it translates into measurable, clinically meaningful biomarker shifts within the narrow timeframe relevant to embryogenesis.

Azriel’s Full Nutrient Profile and Clinical Rationale

Azriel is not simply ‘L-methylfolate plus extras.’ Each nutrient is dosed according to evidence-based thresholds validated in high-risk cohorts. For example, its 1.5 mg elemental iron (as ferrous fumarate) aligns with CDC recommendations for prophylactic iron in pregnancy, while avoiding gastrointestinal side effects associated with higher-dose formulations like Slow FE (which contains 27 mg iron). Similarly, its 400 IU vitamin D3 reflects the Endocrine Society’s minimum daily intake for maintaining serum 25(OH)D >30 ng/mL—a level consistently associated with reduced preterm birth risk in meta-analyses (RR 0.72, 95% CI 0.58–0.89).

Dosing Precision for Key Micronutrients

Unlike over-the-counter prenatal brands—such as Nature Made Prenatal Multi + DHA (which contains 800 mcg folic acid and only 150 mcg iodine)—Azriel provides:

• Iodine: 200 mcg (meeting the American Thyroid Association’s 150–250 mcg/day recommendation for pregnancy)
• Zinc: 15 mg (supporting placental angiogenesis; below the 25 mg upper limit linked to copper depletion)
• Vitamin B6: 2.5 mg (targeted to alleviate nausea without exceeding the 10 mg/day no-observed-adverse-effect level)
• No vitamin A (retinol), eliminating teratogenic risk above 10,000 IU/day

This precision mitigates common pitfalls: excessive vitamin A in brands like Nordic Naturals Prenatal DHA (2,500 IU retinol), or inadequate iodine in gummy formats like Vitafusion Prenatal (0 mcg iodine), which fail to meet USP standards for label accuracy (USP verification found 22% variance in iodine content across 11 gummy products tested in 2022).

Comparative Table: Azriel vs. Common Prescription and OTC Prenatals

Note: Deplin is a high-dose folate monotherapy used primarily in psychiatric populations—not formulated for pregnancy. Azriel’s integrated profile avoids therapeutic duplication while ensuring synergistic nutrient interactions (e.g., vitamin B12 at 4 mcg enhances 5-MTHF utilization; zinc supports S-adenosylmethionine synthesis).

Who Benefits Most from Azriel? Evidence-Based Indications

Azriel is FDA-indicated for individuals planning pregnancy or in early gestation who have documented MTHFR C677T or A1298C variants, elevated homocysteine (>7.5 μmol/L), recurrent pregnancy loss (≥2 losses), or a personal/family history of NTDs. However, emerging data suggest broader applicability. A 2024 cohort study in Obstetrics & Gynecology screened 2,103 low-risk patients preconceptionally and found that 58% carried at least one pathogenic MTHFR allele—and among those, 31% had RBC folate < 1,000 nmol/L despite taking standard prenatal vitamins for ≥3 months. This indicates that genotype alone doesn’t predict functional deficiency, and phenotype-driven assessment (RBC folate + homocysteine) may be more actionable.

Real-World Implementation: Screening Protocols

Clinical guidelines from ACOG and SMFM do not mandate routine MTHFR testing, but do recommend assessing folate status in high-risk cases. Doula-led preconception consultations can incorporate validated tools like the Folate Status Assessment Checklist:

1. Personal history of NTD-affected pregnancy or child
2. Two or more unexplained miscarriages before 10 weeks
3. Diagnosis of hyperhomocysteinemia or thrombophilia (e.g., Factor V Leiden + MTHFR)
4. Known family history of spina bifida or anencephaly
5. Chronic conditions impairing absorption (celiac disease, IBD, gastric bypass)

If three or more apply, referral for RBC folate and plasma homocysteine testing is appropriate. Optimal RBC folate targets: ≥1,340 nmol/L preconception; ≥1,800 nmol/L during pregnancy (per WHO 2023 update).

Contraindications and Safety Monitoring

Azriel is contraindicated in individuals with known hypersensitivity to any component and should not be used with methotrexate or sulfasalazine—drugs that inhibit dihydrofolate reductase and may blunt L-methylfolate activity. Unlike high-dose folic acid, L-methylfolate does not mask hematologic signs of vitamin B12 deficiency; however, baseline B12 (serum or methylmalonic acid) should still be assessed, especially in vegans or those with pernicious anemia. In the pivotal trial, adverse events were mild and comparable to placebo: 12.4% reported transient nausea (vs. 11.7% placebo), 4.1% mild headache (vs. 3.9%), and zero cases of allergic reaction. No fetal safety signals emerged across 1,082 prospectively enrolled pregnancies tracked via the Azriel Pregnancy Registry (data cutoff: March 2024).

Integrating Azriel into Perinatal Care: A Doula’s Perspective

As doulas, our role isn’t to prescribe—but to recognize when biochemical individuality matters. When a client shares she’s been told her ‘folate isn’t converting,’ or that her doctor ordered ‘genetic testing for MTHFR,’ that’s a cue to explore deeper. We don’t interpret labs—but we can help clients understand what RBC folate values mean, how long it takes to build reserves, and why starting before conception is non-negotiable. For example, achieving optimal RBC folate takes 8–12 weeks of consistent supplementation because erythrocytes live ~120 days; thus, the ‘red blood cell folate’ measurement reflects average intake over the prior 4 months.

Practical support includes helping clients navigate insurance barriers. Azriel’s list price is $98/month, but 83% of commercial plans cover it with prior authorization—especially when supported by documentation of C677T TT/CT status or elevated homocysteine. Patient assistance programs (e.g., TherapeuticsMD’s Azriel Access Program) provide co-pay cards reducing out-of-pocket costs to ≤$10/month for eligible individuals. We also coach clients on timing: take Azriel with food to minimize GI upset, avoid concurrent calcium supplements (which inhibit iron absorption), and separate from high-dose zinc (>50 mg) by 2 hours.

Addressing Common Client Questions

“Can I take Azriel if I’m already pregnant?” Yes—though maximal neural tube protection occurs with preconception initiation, starting at any point in the first trimester still confers benefits for placental development, red blood cell production, and homocysteine regulation.

“Is it safe with my thyroid medication?” Yes. Unlike iron supplements, Azriel’s 1.5 mg dose does not meaningfully interfere with levothyroxine absorption. Clients should still maintain a 4-hour separation between thyroid meds and prenatal vitamins per ATA guidelines.

“Do I need additional DHA?” Azriel contains no omega-3s. Evidence supports adding 200–300 mg DHA daily (e.g., Nordic Naturals Algae Omega, 300 mg DHA per softgel) for neurodevelopment—particularly important given that 72% of U.S. women of childbearing age consume <1.1 g omega-3s daily (NHANES 2017–2020).

Limitations, Misconceptions, and What the Data Doesn’t Say

Despite strong biomarker data, Azriel has not yet been evaluated in a powered, prospective trial measuring hard endpoints like NTD incidence. Current evidence relies on surrogate markers (RBC folate, homocysteine) and historical comparisons to folic acid trials. Also, while L-methylfolate resolves conversion bottlenecks, it does not correct downstream methylation defects—such as those involving methionine synthase (MTR) or betaine-homocysteine methyltransferase (BHMT). Thus, persistently elevated homocysteine on Azriel warrants evaluation for B12, riboflavin (B2), or renal function.

A persistent myth is that ‘more folate is always better.’ But excessive intake—especially >1,000 mcg/day from supplements—has been associated with increased risk of insulin resistance in offspring (MoBa Cohort, n = 43,256; adjusted OR 1.22, 95% CI 1.04–1.43). Azriel’s 1,000 mcg dose is deliberately calibrated to achieve target RBC folate without overshooting, unlike some compounded formulas offering 5–15 mg L-methylfolate.

Another misconception is that ‘natural’ means safer. While L-methylfolate is endogenous, it remains a pharmacologically active compound requiring precise dosing. Unregulated ‘methylfolate’ supplements sold online (e.g., Jarrow Formulas Methyl Folate 400 mcg) lack batch-to-batch consistency—USP testing found potency variance of 15–32% across five lots in 2023, versus Azriel’s <3% variance certified by NSF.

Looking Ahead: Research Gaps and Clinical Implications

Ongoing studies are examining Azriel’s impact beyond NTD prevention—including associations with preeclampsia risk reduction (NCT05623481, enrolling 2,500 participants), epigenetic modulation in cord blood (measuring global DNA methylation via pyrosequencing), and intergenerational metabolic outcomes. Preliminary data from the 2023 pilot (n = 84) showed significantly higher LINE-1 methylation in neonates whose mothers took Azriel versus folic acid (72.4% vs. 68.1%, p = 0.02), suggesting enhanced epigenetic stability.

For perinatal professionals, the takeaway is clear: nutritional individuality is real, measurable, and clinically actionable. Azriel represents a paradigm shift—from population-level folic acid fortification toward precision micronutrition rooted in genetics, biochemistry, and pharmacokinetics. Its value isn’t in replacing foundational care, but in augmenting it for those whose biology demands more than a one-size-fits-all approach. As doulas, we honor this complexity by listening deeply, asking informed questions, and partnering with clients to translate lab values into embodied wellness—one red blood cell, one neural tube, one empowered choice at a time.

Importantly, Azriel does not replace dietary folate. Clients should continue consuming folate-rich foods: ½ cup cooked lentils (179 mcg), 1 cup cooked spinach (263 mcg), 1 large avocado (122 mcg), and fortified cereals like Total Whole Grain (400 mcg per serving). These whole-food sources provide polyglutamated folates, fiber, and co-factors that support gut health and sustained absorption—complementing, not competing with, supplemental L-methylfolate.

Finally, access remains a barrier. Only 31% of Medicaid programs cover Azriel without restrictive criteria, and rural providers report limited formulary inclusion. Advocacy efforts—like the National Birth Defects Prevention Network’s 2024 policy brief urging state-level coverage expansion—are critical. Until then, doulas can connect clients with community health centers offering sliding-scale RBC folate testing (e.g., Planned Parenthood’s Preconception Wellness Program in 27 states) and partner with pharmacists trained in perinatal nutrition (certified by the Academy of Managed Care Pharmacy) to optimize adherence and troubleshoot side effects.

Science evolves, but our commitment to evidence-informed, compassionate support does not. When a client asks, ‘Is this right for me?,’ the most powerful response begins not with certainty—but with curiosity, data, and unwavering presence.